GSK now expects 20+ phase III trial starts in 2026, up from 10

Reuters2026/07/28 11:18

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

GSK lifted its 2026 R&D outlook, now targeting more than 20 Phase III trial starts versus 10 previously.
The updated expectations follow Q2 2026 performance with total sales of £8.4 billion, up 5%, core operating profit of £2.8 billion, up 7%.
Management flagged a 3-year cost-savings program to fund late-stage portfolio investment, with some savings aimed at supporting margins in 2028-2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

GSK now expects 20+ phase III trial starts in 2026, up from 10

You may also like

Crypto prices